After Redchip’s announcement this morning that Pressure BioSciences would be a featured company in their upcoming investor conference, prices surged to reach a High-of-Day at $6.82, which is 18.2% higher than yesterday’s close. Volume also exploded reaching a 852% increase compared to the 15 day average.

Dutton Associates recently issued a research note reiterating their “Strong Speculative Buy” rating and initiating price target of $10. In conclusion of the independent report, the analyst stated, “In sum, we believe that Pressure BioSciences has attained its short-term goals regarding commercialization and is well poised to continue to market its PCT systems in the U.S. along with its plan to expand overseas by collaborating with appropriate research laboratories. We reiterate our Strong Speculative Buy rating with a 12-month target of $10.00.”

The company announced last month that total revenues increased from $92,211 in the third quarter of 2006 to $138,052 for the same quarter of this year. The primary cause of the increase can be attributed to the increased number of installations of the Company’s Pressure Cycling Technology (PCT) Sample Preparation Systems. The innovative systems can be used in an array of possible applications including genomics and proteomics, in addition to drug discovery, pathogen inactivation, food safety, immunodiagnostics, and DNA sequencing.

A video demonstrating the technology can be found at the following link: http://www.pressurebiosciences.com/videos/video.html

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board